Fiche d'information compilée à partir de PubMed
Cette fiche a été compilée à partir de résumés PubMed (NIH) avec l'assistance d'une IA. Chaque affirmation factuelle est citée par un article PubMed réel (voir la liste des sources). Elle n'a pas encore été révisée par un humain — confirmez auprès d'un professionnel de santé avant utilisation.
Compilé à partir de 30 articles PubMed · modèle : gemma4:31b
Résumé
Contexte
Usages traditionnels
Composés actifs
Mécanisme d'action
Preuves cliniques
Supplementation of mulberry leaf/extract resulted in a significant reduction of glycemic traits [PMID:36644880]. In a trial of 60 patients, 300 mg of extract twice daily significantly decreased insulin and malondialdehyde (MDA) and increased HDL-cholesterol [PMID:35623877].
Different doses of Reducose mulberry leaf extract were investigated for their ability to lower glycemic and insulinemic responses to a meal in healthy individuals [PMID:38892603].
A blend containing 750 mg of mulberry leaf extract and tryptophan was evaluated for benefits on sleep onset latency and efficiency in adults with sleep complaints [PMID:40072601].
Sécurité et effets indésirables
Synthèse des preuves
Sources PubMed
- 1.PMID: 40527063 (2025) — Mulberry leaf improves type 2 diabetes in mice via gut microbiota-SCFAs-GPRs axis and AMPK signaling pathway. · Phytomedicine : international journal of phytotherapy and phytopharmacology
- 2.PMID: 38892603 (2024) — Understanding the Impact of Different Doses of Reducose® Mulberry Leaf Extract on Blood Glucose and Insulin Responses after Eating a Complex Meal: Results from a Double-Blind, Randomised, Crossover Trial. · Nutrients
- 3.PMID: 36770881 (2023) — Biosynthesized Silver Nanoparticles Using Morus alba (White Mulberry) Leaf Extract as Potential Antibacterial and Anticancer Agents. · Molecules (Basel, Switzerland)
- 4.PMID: 40678263 (2025) — Oral oncolytic magnetotactic bacteria elicit anti-colorectal tumor immunity and reprogram microbiota metabolism. · Bioactive materials
- 5.PMID: 41004579